In Vitro Antibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases
Open Access
- 1 April 2015
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (4), 1931-1934
- https://doi.org/10.1128/aac.04218-14
Abstract
The novel β-lactamase inhibitor avibactam is a potent inhibitor of class A, class C, and some class D enzymes. The in vitro antibacterial activity of the ceftazidime-avibactam combination was determined for a collection of Enterobacteriaceae clinical isolates; this collection was enriched for resistant strains, including strains with characterized serine β-lactamases. The inhibitor was added either at fixed weight ratios to ceftazidime or at fixed concentrations, with the latter type of combination consistently resulting in greater potentiation of antibacterial activity. In the presence of 4 μg/ml of avibactam, the ceftazidime MIC 50 and MIC 90 (0.25 and 2 μg/ml, respectively) were both below the CLSI breakpoint for ceftazidime. Further comparisons with reference antimicrobial agents were performed using this fixed inhibitor concentration. Against most ceftazidime-susceptible and -nonsusceptible isolates, the addition of avibactam resulted in a significant increase in ceftazidime activity, with MICs generally reduced 256-fold for extended-spectrum β-lactamase (ESBL) producers, 8- to 32-fold for CTX-M producers, and >128-fold for KPC producers. Overall, MICs of a ceftazidime-avibactam combination were significantly lower than those of the comparators piperacillin-tazobactam, cefotaxime, ceftriaxone, and cefepime and similar or superior to those of imipenem.This publication has 10 references indexed in Scilit:
- Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012Antimicrobial Agents and Chemotherapy, 2014
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniaeInternational Journal of Antimicrobial Agents, 2012
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitorsCurrent Opinion in Microbiology, 2011
- Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-LactamasesAntimicrobial Agents and Chemotherapy, 2011
- In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermentersJournal of Antimicrobial Chemotherapy, 2010
- Diversity, Epidemiology, and Genetics of Class D β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemasesJournal of Antimicrobial Chemotherapy, 2009
- In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitorJournal of Antimicrobial Chemotherapy, 2004
- Selection during Cefepime Treatment of a New Cephalosporinase Variant with Extended-Spectrum Resistance to Cefepime in an Enterobacter aerogenes Clinical IsolateAntimicrobial Agents and Chemotherapy, 2004
- Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of anEnterobacter cloacaeclinical isolateFEMS Microbiology Letters, 2001